Wednesday , March 29 2017
Home / 2015 / May

Monthly Archives: May 2015

Heron’s Investigational CINV Drug Succeeds in Late-Stage Study

Heron Therapeutics said that its experimental drug for treating chemotherapy-induced nausea and vomiting (CINV) met its primary endpoint in a late-stage study. Following repeated delays, the positive news sent the company’s shares up more than 40 percent in extended trading. Heron announced top-line results from its Phase III MAGIC study, …

Read More »

Pfizer’s Rapamune Receives FDA Approval for Treatment of Rare Lung Disease

Today, Pfizer Inc. announced that US health regulators approved the first drug to treat a rare, progressive lung disease. The company said that the US Food and Drug Administration (FDA) approved its Rapamune (sirolimus) for the treatment of lymphangioleiomyomatosis (LAM), a rare, progressive disease that affects the lungs, kidneys and …

Read More »

Merck Files for Approval of its Single Tablet Hep C Combo Therapy

Merck announced that it has submitted for approval of its Breakthrough single tablet combination therapy for treatment of patients with hepatitis C to US health regulators. The company said that it submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for grazoprevir/elbasvir (100mg/50mg), an investigational …

Read More »

Novartis Collaborates with Rani to Develop “Robotic Pill”

Novartis AG recently announced that it is partnering with Google-backed startup Rani Therapeutics on a “robotic pill” that would make complex injectable drugs available through oral administration. The companies announced that they have entered into a collaboration to evaluate Rani’s novel oral biotherapeutics drug delivery platform, and have agreed to …

Read More »

Cerulean Pharma’s Ovarian Cancer Drug Granted Orphan Drug Status

The US Food and Drug Administration (FDA) has granted Orphan Drug designation to Cerulean Pharma Inc.’s investigational ovarian cancer drug. The company announced that the agency granted the designation to its nanoparticle-drug conjugate (NDC), CRLX101, for the treatment of patients with ovarian cancer. The designation provides certain incentives, such as …

Read More »

Pfizer Survey Demonstrates Importance of Shared Decision-Making Practices to Improve Patient Outcomes in RA

Data from a new survey, conducted by Pfizer, found that a patient’s perception of their rheumatoid arthritis (RA) and its treatment, as well as their relationship with their healthcare professional (HCP), can impact the management of their disease. Pfizer announced initial results from the global survey, called RA NarRAtive, consisting …

Read More »

This Year’s $50,000 Prescription Bill

It may not be breaking news, but prescription costs continue to skyrocket. Express Scripts, a pharmacy-benefit management company, recently released a report entitled “Super Spending: U.S. Trends in High-Cost Medication Use” which examines the prescription drug use of nearly 32 million Americans over the past two years. The numbers revealed …

Read More »

AbbVie Completes $21 Billion Acquisition of Pharmacyclics

AbbVie has completed its $21 billion acquisition of Pharmacyclics, Inc., strengthening its oncology portfolio. The company said that it has completed the acquisition of Pharmacyclics, a leader in the hematological oncology market with its blockbuster drug Imbruvica (ibrutinib). Imbruvica is a first-in-class BTK-inhibitor used to treat hematological cancers, a $24 …

Read More »

Sanofi Pays $245 Million for Retrophin’s Priority Review Voucher

Retrophin, Inc. has sold its priority review voucher to Sanofi for $245 million in cash. In March, Retrophin bought small drugmaker, Asklepion Pharmaceuticals, for roughly $75 million, gaining Cholbam (cholic acid), a drug approved by the US Food and Drug Administration (FDA). Retrophin has already gained that $75 million back …

Read More »

Bluebird Bio Enters CAR T Deal with Five Prime

Bluebird bio announced that it has entered into an immuno-oncology deal with Five Prime Therapeutics. The companies said that they have entered into an exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies. Under the agreement, the companies will use Five Prime’s proprietary human …

Read More »